Amorfix teams with PREVENT for vaccine candidates

Guest Contributor
June 18, 2010

Toronto's Amorfix Life Sciences Ltd has granted exclusive worldwide rights for the commercialization of its lead amyotrophic lateral sclerosis (ALS) vaccines to Pan-Provincial Vaccine Enterprise Inc (PREVENT). PREVENT — a Centre of Excellence for Commercialization and Research (CECR) — will take over clinical development of Amorfix's lead vaccine candidates for ALS. The cost-sharing, revenue-sharing agreement will see PREVENT develop vaccine formulations, complete preclinical studies for regulatory approval and conduct clinical testing at their cost. Amorfix retains the rights to develop antibodies and diagnostics for ALS....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.